A federal court jury in the U.S. District Court for the Northern District of California unanimously found Natera, Inc. liable for false advertising and unfair competition. The verdict was in favor of Guardant Health, Inc., a competitor in the ctDNA space.
The jury awarded Guardant Health $292.5 million in damages, which included $175.5 million in punitive damages. This represents a substantial financial penalty for Natera.
Natera stated its disagreement with the decision and announced plans to ask the Court to overturn it. The company emphasized that the case concerned comparative advertisements from 2021 related to Guardant’s Reveal test and that certain key pieces of evidence supporting Natera’s case were not included in the trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.